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A r t i c l e s
Lethal autoimmune diseases can develop in the absence of effective immunosuppressive mediators. Regulatory T cells (T reg cells) are necessary for immune homeostasis and to prevent autoimmunity, yet they also limit antitumor immunity 1, 2 . T reg cells use a broad range of mechanisms to suppress immunity, including suppressive cytokines such as IL-35, IL-10 and TGF-β. IL-35 belongs to the IL-12 family of cytokines, which also includes IL-12, IL-23 and IL-27. These cytokines are heterodimeric proteins composed of shared α-chains (p19 (encoded by Il23a), p28 (encoded by Il27) and p35 (encoded by Il12a)) and β-chains (p40 (encoded by Il12b) and Ebi3 (encoded by Ebi3)), are produced by antigen-producing cells and have immunomodulatory activities. IL-12 and IL-23 are proinflammatory cytokines that can promote differentiation into the T H 1 and T H 17 subsets of helper T cells and can promote the function of T H 1 and T H 17 cells 3 . IL-27 serves to initiate T H 1 polarization but has a host of immunomodulatory activities, including limiting T helper type 2 (T H 2) activity 4 and blocking T H 17 differentiation and the TGF-β-driven formation of induced T reg cells and IL-10 production [5] [6] [7] . IL-35 (composed of p35 and Ebi3) is distinct from other family members in that it is produced by T reg cell populations and is suppressive. In vitro and in vivo, IL-35 has two known biological effects: suppression of the proliferation of conventional T cells (T conv cells), and the conversion of naive T conv cells into a strongly suppressive induced T reg cell population, called 'iTr35 cells' , which function via IL- 35 (refs. 8-10) . Thus, a chief downstream target of signaling via the IL-35 receptor (IL-35R) is induction of the transcription of Il12a and Ebi3.
Chain sharing extends beyond the cytokines to their receptors and signaling pathways. IL-12Rβ1 (encoded by Il12rb1) and IL-12Rβ2 (encoded by Il12rb2) form the IL-12 receptor 11 , whereas IL-23 signals through a receptor of IL-12Rβ1 paired with IL-23R (encoded by Il23r) 12 . In contrast, IL-27 uses the receptor chains gp130 (encoded by Il6st) and IL-27R (WSX-1 or TCCR; encoded by Il27ra) 13 . Although use of IL-12Rβ1, IL-12Rβ2, IL-23R and IL-27R is restricted to receptors for the IL-12 family of cytokines, gp130 is ubiquitously expressed and is a component of receptors for many cytokines, including IL-6, IL-11, leukocyte-inhibitory factor (LIF), oncostatin M, ciliary neurotrophic factor (CNTF), cardiotrophin 1 and cardiotrophin-like cytokine 14 .
After engagement of the receptor, signaling is initiated by activation of members of the Janus kinase family, followed by phosphorylation and nuclear localization of members of the signal transducer and activator of transcription (STAT) family 12, 15 . A major conundrum in cytokine signaling is explaining how so many cytokines (over 50) can mediate such diverse functional events via only seven STAT proteins 16 . Although multiple STAT proteins can be phosphorylated after receptor engagement, usually only one or two are essential.
RESULTS

Suppression by IL-35 occurs via IL-12Rb2 or gp130
IL-35 mediates two distinct functions in T cells: suppression of proliferation and conversion into suppressive iTr35 cells 8, 10 . Thus, two anticipated functional phenotypes of genetic manipulation of IL-35R expression would be resistance to IL-35-mediated suppression and prevention of the conversion into iTr35 cells. We first sought to determine whether IL-35 suppressed the proliferation of CD4 + CD45RB hi CD25 − naive CD4 + T conv cells that lacked expression of each of the IL-12 receptor chains. For these experiments we used either recombinant IL-35 derived from HEK293T (293T) human embryonic kidney cells (soluble or (to eliminate any potential effects of supernatants of those cells) protein G beads coupled with either IL-35 conjugated via a non-neutralizing mAb specific for p35 or an isotype-matched control mAb 8, 10 . The ability of IL-35 to suppress Il27ra −/− and Il12rb1 −/− T conv cells was similar to its ability to suppress wild-type T conv cells (Supplementary Fig. 1a ). In contrast, T conv cells that lacked expression of either IL-12Rβ2 (from Il12rb2 −/− mice) or gp130 (from the progeny of mice expressing Cre recombinase from the Cd4 promoter (CD4 cre mice) and mice with loxP-flanked Il6st alleles (Il6st fl/fl ); called 'Il6st ∆T mice' here) were partially resistant to IL-35-mediated suppression ( Fig. 1a and Supplementary Fig. 2a) (Fig. 1b) . Consistent with the results obtained with recombinant IL-35, T conv cells that lacked expression of IL-12Rβ2 or gp130 alone also seemed partially resistant to iTr35 cell-mediated suppression. However, loss of both chains of the IL-35R (IL-35R ∆T ) rendered cells completely resistant to iTr35 cell-mediated suppression (Fig. 1b) Fig. 1b) . Nevertheless, this defect was limited because of the many alternative regulatory mechanisms available to nT reg cells 1 . However, nT reg cells activated in the presence of T conv cells in the upper chamber of a Transwell plate can mediate potent IL-35-dependent, contactindependent suppression of T conv cells in the bottom well 9 . Whereas wild-type T conv cells were potently suppressed by nT reg cell-T conv cell cocultures, IL-35R ∆T T conv cells were completely resistant to this (Supplementary Fig. 1c ). Together these data suggested that T conv cells lacking both gp130 and IL-12Rβ2, but not T conv cells lacking IL-12Rβ1 and IL-27R (WSX-1), were resistant to IL-35-mediated suppression regardless of source. Unexpectedly, T conv cells lacking just one chain of the putative IL-35R were partially resistant in the in vitro suppression assays, which suggested that signaling can occur with the expression of only one chain of IL-35R.
Conversion to iTr35 cells requires both gp130 and IL-12Rb2
In addition to suppressing T cell proliferation, IL-35 also can induce the expression of Ebi3 and Il12a and the conversion of T conv cells into iTr35 cells. We determined if loss of one chain or both chains of the putative IL-35R affected the ability of receptor chain-deficient T conv cells to convert into iTr35 cells. Although activation of naive wild-type T conv cells in the presence of IL-35 resulted in considerable upregulation of Ebi3 mRNA and Il12a mRNA, deficiency in either receptor chain blocked IL-35 upregulation (Fig. 2a) . Furthermore, whereas wild-type cells that had been cultured in the presence of IL-35 differentiated into iTr35 cells that were much more suppressive than those cultured in the presence of control supernatant (iTrCon cells), Il12rb2 −/− and Il6st ∆T cells cultured in the presence of IL-35 failed to develop a suppressive iTr35 phenotype (Fig. 2b) . Despite the finding that Il12rb2 −/− and Il6st ∆T T conv cells were only partially resistant to IL-35-mediated suppression in vitro, they failed to convert into suppressive iTr35 cells. These data suggested that single-chain signaling was sufficient for partial IL-35-mediated suppression but that a complete IL-35R (IL-12Rβ2 and gp130) was needed to induce IL-35 production. (Fig. 3a) .
IL-35R-deficient T cells are resistant to IL-35 in vivo
The iTr35 cells can also block the antitumor CD8 + T cell response to B16 melanoma, thereby facilitating tumor growth. We adoptively transferred wild-type, Il6st ∆T , Il12rb2 −/− or IL-35R ∆T CD4 + T cells and CD8 + T cells, either alone or together with iTr35 cells, into Rag1 −/− mice. The next day, we inoculated mice intradermally with B16 melanoma cells and measured tumors after 14 d. In the absence of iTr35 cells, tumor burden was similar in mice that received CD4 + T cells and CD8 + T cells, regardless of genotype (Fig. 3b) . When present, iTr35 cells blocked antitumor immunity in recipients of wildtype, Il6st ∆T 
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Figure 2 [20] [21] [22] .
IL-35 induces hetero-and homodimers of gp130 and IL-12Rb2
To obtain direct physical evidence that IL-35 binds to gp130 and IL-12Rβ2, we first used laser-scanning spinning-disc confocal microscopy combined with total internal reflection fluorescence (TIRF) illumination and detection based on fluorescence resonance energy transfer (FRET). We transiently expressed IL-12Rβ2 tagged with the red fluorescent protein mCherry, plus either IL-12Rβ1 or gp130 tagged with green fluorescent protein (GFP), on 293T cells. As expected, we observed a significantly higher normalized FRET (nFRET) signal for cells expressing IL-12R (IL-12Rβ2 and IL-12Rβ1) after the addition of IL-12 but not after the addition of IL-35 ( Fig. 4a) . Similarly, we observed a significantly higher nFRET for cells expressing the putative IL-35R (IL-12Rβ2 and gp130) after the addition of IL-35 but not after the addition of control supernatant derived from 293T cells (Fig. 4b) . The most likely mechanism of IL-35-induced signaling via a single chain is homodimerization. However, we did not detect homodimerization of gp130 or IL-12Rβ2 by this approach (with gp130-GFP and gp130-mCherry; data not shown). It is possible that homodimeric receptors associate with lower affinity and/or kinetics or with an altered mode of assembly (distance and/or rotation), which may limit FRET efficiency.
As an alternative approach, we used the fluorescent protein-tagged receptor chains described above in coimmunoprecipitation experiments. We cotransfected various combinations of receptor constructs into 293T cells and treated those cells with 293T cell-derived IL-12 or IL-35. We crosslinked surface receptors and immunoprecipitated then with antibody specific for mCherry, followed by detection of GFP by immunoblot analysis. As expected, IL-12 induced the heterodimerization of IL-12Rβ1 and IL-12Rβ2 but not that of any of the other receptor-chain combinations tested (Fig. 4c,d ). Consistent with our results obtained for FRET, IL-35 induced the homodimerization and heterodimerization of gp130 and IL-12Rβ2 ( Fig. 4c,d ). These results suggested that IL-35 bound to three receptor combinations, which provided mechanistic insight into the partial resistance to IL-35-mediated suppression observed after the deletion of a single chain. It should be noted that although we have used the term 'dimerization' here as the minimal likely mode of receptor association, we cannot rule out the possibility of the assembly of higher structures by IL-35, as has been suggested for IL-6 (ref. 23) . Together with the functional analysis reported above, these data confirmed that IL-12Rβ2 and gp130 represent the most plausible components of IL-35R. However, additional molecules might facilitate cytokine binding or downstream signaling, although this would be unprecedented in the IL-6R and IL-12R families 14, 24 .
IL-2 and IL-27 induce IL-35R expression
We next assessed the pattern of IL-35R expression and how this might correlate with and be used to predict cellular sensitivity to IL-35. 25, 26 .
Optimal responsiveness of T conv cells to IL-12 requires activation in the presence of IL-2 or IL-27, which upregulate expression of the IL-12β2 receptor chain [27] [28] [29] . Consistent with those published observations, activation of T conv cells in the presence of increasing doses of IL-2 or IL-27 induced higher expression of Il12rb2 (Fig. 5a) . The addition of neutralizing antibody to IL-2 resulted in little to no upregulation of Il12rb2 after stimulation of the T cell antigen receptor, which suggested that autocrine IL-2 was required for higher receptor expression after T cell activation. In our system, the expression of Il12rb1 and Il6st did not change appreciably after activation with either IL-2 or IL-27 (Fig. 5a) .
To examine the biological consequences of receptor upregulation, we activated T conv cells in the presence of IL-2 or IL-27 or neutralizing antibody to IL-2 and allowed the cells to 'rest' . We then restimulated those previously activated T cells in the presence of titered amounts of IL-35, with fresh T conv cells included for comparison. T conv cells activated in the presence of IL-2 or IL-27 were significantly more sensitive to IL-35 treatment than were T conv cells activated in their absence or fresh T conv cells (Fig. 5b,c) .
Analysis of T H 1, T H 2 and T H 17 cells showed variable expression of IL-35R chains (Supplementary Fig. 2) . Notably, T H 1 cells had much higher expression of Il12rb2 than did T conv cells, T H 2 or T H 17 cells, whereas T H 1 and T H 2 cells had higher expression of Il6st than did T conv cells or T H 17. T conv cells, T H 1 cells and T H 2 cells were all susceptible to IL-35-mediated suppression, whereas T H 17 cells were resistant to this (V.C. et al., unpublished results). Thus, whereas expression of IL-35R chains probably influenced susceptibility to IL-35-mediated suppression, other factors may have also contributed to this. Nevertheless, our data indicated IL-2 and IL-27 were inducers of IL-35R upregulation and thus of sensitization to IL-35-mediated suppression.
IL-35 signals through STAT1 and STAT4
Given that IL-35R used IL-12Rβ2 and gp130, it seemed logical that signaling would be mediated via the STAT family of transcription factors. Consistent with published reports 27, 28 , the treatment of T conv cells with IL-12 resulted in intracellular phosphorylation of STAT4, whereas IL-27 signaling induced the phosphorylation of STAT1 and STAT3 (Fig. 6a) . The treatment of wild-type T conv cells with IL-35 resulted in phosphorylation of STAT1 and STAT4 but no activation of either STAT3 or STAT5 above background. Moreover, we observed no induction of phosphorylated STAT1 or STAT4 in T conv cells that lacked IL-35R. Immunoblot analysis confirmed substantial induction of phosphorylated STAT1 but somewhat less activation of phosphorylated STAT4 in T conv cell blasts treated with IL-35 (Fig. 6b) . (Fig. 6c,d ). These data further confirmed the ability of IL-35 to mediate signaling in the presence of only one of the IL-35R chains.
Given that T cells expressing only one IL-
To determine which STAT proteins were needed to mediate IL-35 signaling, we examined the susceptibility of T conv cells that lacked STAT1, STAT3 or STAT4 to IL-35-mediated suppression. Whereas IL-35 suppressed the proliferation of Stat3 ∆T T conv cells (from the progeny of CD4 cre mice crossed with mice with loxP-flanked Stat3 alleles (Stat3 fl/fl )) to a degree similar to that of wild-type T conv cells, the suppression of Stat1 −/− and Stat4 −/− T conv cells was significantly lower (Fig. 6e) . Similarly, nT reg cell-mediated suppression of Stat1 −/− and Stat4 −/− T conv cells, but not of Stat3 ∆T T conv cells, was also impaired (Supplementary Fig. 3) . Notably, expression of Il12rb2 mRNA and Il6st mRNA was similar in Stat1 −/− , Stat4 −/− and wild-type T conv cells (data not shown). Collectively, these data suggested that both STAT1 and STAT4 were required for maximal IL-35-mediated suppression.
IL-35 uses a unique STAT1-STAT4 heterodimer IL-35 can convert T conv cells into hyporesponsive, strongly suppressive iTr35 cells 8 . Thus IL-35 signaling induces the expression of Ebi3 and Il12a, the production of IL-35 and the generation of iTr35 cells. Mutant cells deficient in one chain of IL-35R that were able to activate only one of the two required STAT proteins did not convert into iTr35 cells (Fig. 2) . This suggested that both STAT1 signaling and STAT4 signaling downstream of IL-35R were required for the induction of transcription of Ebi3 and Il12a, a prerequisite for conversion of T cells into iTr35 cells. IL-35 induced much less transcription of Ebi3 and Il12a in STAT1-or STAT4-deficient T conv cells than in wild-type cells (Supplementary Fig. 4a ), which indicated a coordinated role for those transcription factors in mediating IL-35 production and the conversion into iTr35 cells. Given the rapid increase in Ebi3 and Il12a expression after stimulation with IL-35 (1-3 h), it was unlikely that signaling occurred through an intermediate step (Supplementary Fig. 4b) .
Several cytokine receptors activate STAT1 and STAT4 to drive proinflammatory T H 1-type responses, so it is unclear how their activation via IL-35R could give rise to a very different outcome. Two well-known activators of STAT1 and STAT4 are IFN-γ and IL-12, respectively 17, 30 . Treatment of activated T conv cells with IL-12 plus IFN-γ or with IL-35 alone induced the activation of STAT1 and STAT4 (Fig. 7a) . However, T conv cells stimulated with IL-12 plus IFN-γ did (Fig. 7b) and thus would not secrete IL-35 or become iTr35 cells. Therefore, the activation of STAT1 and STAT4 by IL-35 led to distinct outcomes.
Although cytokine signals generally induce the homodimerization of STAT proteins, which promotes their translocation to the nucleus, STAT1-STAT2 and STAT1-STAT3 heterodimerization has been linked to signaling via interferons and the IL-6 receptor, respectively 31 . Reciprocal coimmunoprecipitation and immunoblot analysis demonstrated that stimulation with IL-35 induced the formation of a STAT1-STAT4 heterodimer (Fig. 7c) . In contrast, treatment of activated T conv cells with IL-12 plus IFN-γ failed to induce appreciable formation of STAT1-STAT4 heterodimers despite potent activation of both STAT proteins (Fig. 7a,c) . These data suggested that IL-35 can mediate signaling consequences distinct from those of IFN-γ and IL-12 by inducing the formation of a STAT1-STAT4 heterodimer.
Given that transcription of Il12a and Ebi3 is an exclusive direct downstream consequence of IL-35R signaling, we sought to determine if STAT1-STAT4 heterodimers had a distinct binding pattern in the promoters of those genes. In silico analysis of the Il12a and Ebi3 promoters with a proposed consensus STAT motif (TTC-N 1-5 -AGA, where 'N 1-5 ' indicates a range of one to five residues of any nucleotide, and allowing for mismatch) identified nine potential binding sites 32, 33 (Fig. 7d) . We designed primers to investigate six of those sites by chromatin immunoprecipitation (ChIP) analysis with anti-STAT1 and anti-STAT4 (Supplementary Table 1) . As a control, we also did ChIP analysis of known STAT1-and STAT4-binding sites in the Irf1 promoter and Il18ra promoter, respectively 34, 35 (Fig. 7e,f) (Fig. 7g) . However, T cells stimulated with IL-35 showed considerable enrichment for the binding of STAT1 and STAT4 to Il12a position −250 and Ebi3 position −500, as well as other sites in the promoters (Fig. 7g) . Although the amplicons used contained only one putative consensus STAT-binding sequence, we cannot rule out the possibly that STAT 1 and STAT4 might bind at adjacent sites that are either in this amplicon or in the fragments generated during DNA shearing. These data indicated the involvement of a STAT1-STAT4 heterodimer as the unique biochemical effector of IL-35 signaling, and STAT1-STAT4 seemed to specifically bind to many sites in the Il12a and Ebi3 promoters. 
Potential configurations of IL-35 receptors
npg
A r t i c l e s site 3 of the cytokine engages the amino-terminal immunoglobulin domain of the signaling receptor; thus, the presence of an aminoterminal immunoglobulin domain is required for it to act as a binder of site 3 (Fig. 8) . The absence of an amino-terminal immunoglobulin domain-for example, as in IL-27R (WSX-1) and IL-12Rβ1-would seem to relegate these receptors to binding to site 2. Although there are no known crystal structures of the IL-12, IL-27 or IL-23 receptor signaling complexes, the present models of IL-12-IL-12R interaction suggest that the IL-12Rβ2 immunoglobulin domain binds to site 3 on the p35 subunit while also interacting with the p40 subunit via its amino-terminal domain 20, 21, 24, 37 (Fig. 8b) . However, in the IL-27-IL-27R complex, gp130 is also predicted to bind to site 3 in the p35 homolog p27 (ref. 24 ). This presents a conundrum, as IL-12Rβ2 and gp130 both contain amino-terminal immunoglobulin domain that could serve as the site 3-interacting domain, yet clearly both cannot bind to the same site; this suggests differences in the formation of the IL-35-IL-35R complex versus that of the the IL-12 and IL-27 receptor complexes. There are three possibilities (Fig. 8c) . First, gp130 binds to site 2 in the IL-6, CNTF and LIF complexes 24 and thus could do so in the IL-35-IL-35R complex, leaving IL-12Rβ2 to bind to site 3. Second, the IL-35-IL-35R complex could form symmetric homohexameric assemblies (2:2:2) analogous to the IL-6R complex 23 , thus allowing IL-12Rβ2 and gp130 to each bind to site 3 on p35. Third, gp130 and IL-12Rβ2 could both be capable of binding to site 2 and site 3 and therefore exist in an interchanging equlibrium of heterotetrameric complexes (at a ratio of 1:1:1:1, gp130 to IL-12Rβ2 to Ebi3 Fig. 8c, left two models) . Indeed, studies of the IL-6 complex suggest that it may be able to signal as tetrameric or hexameric assembly 23 . Finally, a previously unknown mode of binding may exist that uses the site 1-2-3 model in a manner not predicted on the basis of the existing structural information for IL-6, LIF and CNTF 24, 36, 38 . Although a definitive answer will require detailed structural analysis of IL-35-IL-35R, it is notable that the IL-35-neutralizing antibodies we have described, which are specific for Ebi3, can immunoprecipitate IL-27 and IL-35 but neutralize only IL-35, whereas those specific for p35 can immunoprecipitate IL-12 and IL-35 but neutralize only IL-35. This further supports the idea that formation of the IL-35-IL-35R complex is distinct and differs from formation of the IL-12 and IL-27 receptor complexes.
DISCUSSION
The family of cytokines that share gp130-related receptors is the most actively growing subgroup of the type I cytokine family, with the most recent addition being IL-35. In this study we have demonstrated notable similarities and differences among IL-12, IL-27 and IL-35 in their signaling. Given that IL-35 is part of the IL-12 cytokine family, it was reasonable to presume that IL-35R might share use of receptor chains and use common signaling molecules. However, as the biological activity of IL-35 contrasts with that of other members of its cytokine family, commonality in signaling could not be assumed. We found that the receptor and signaling pathway of IL-35 did overlap that of IL-12, in that IL-35R included IL-12Rβ2, which is part of IL-12R, and of IL-27, in that IL-35R included gp130, which is part of IL-27R. However, in contrast to IL-12 and IL-27, IL-35 was able to signal through a single receptor chain, with gp130 alone inducing phosphorylated STAT1, and IL-12Rβ2 inducing phosphorylated STAT4. Indeed, in the absence of either one of the IL-35R chains in vivo, the suppressive effects of IL-35 remained intact. Loss of both IL-12Rβ2 and gp130 was required for complete abrogation of IL-35 activity in vivo. Given the present understanding of receptor signaling and our data reported here, IL-35 seems to mediate the homodimerization of either IL-12Rβ2 or gp130, as well as IL-12Rβ2-gp130 heterodimerization. However, we cannot entirely rule out the possibility that the various forms of IL-35R may form higher-order multimers of those receptor chains. It has been shown that gp130 is able to signal either as a homodimer (for example, with IL-6-soluble IL-6Rα or viral IL-6) or as a heterodimer with the LIF receptor (for example, with CNTF and LIF). This is also a formal possibility for the use of IL-12Rβ2, which so far is known only in a heterodimeric context in the IL-12R complex. Whether signaling induced by IL-35 can be productively mediated via a single IL-35R chain in all physiological conditions and disease scenarios remains to be determined. However, the complete IL-12Rβ2-gp130 receptor is required for maximal suppression, IL-35 induction and conversion to an iTr35 state.
IL-27 activates a heterogeneous mixture of STAT proteins depending on the cell type in question, although in T cells STAT1 and STAT3 dominate 22, 27, 28, 39 . Like IL-27, IL-35 signaled through two different STAT proteins, STAT1 and STAT4. However, STAT3 seemed dispensable for IL-35 signaling, a notable observation given its importance for IL-27 signaling, which is downstream of gp130 engagement. Signaling by the IL-12 family of cytokines involves the phosphorylation of many different STAT proteins, which can form homodimers, thereby acting alone to influence gene transcription, or can form heterodimers to work in concert to elicit an alternative response. The intensity as well as the kinetics of STAT activation have been shown before to influence downstream signaling events, gene expression and the nature of the biological response. For example, IFN-α signaling in myeloid cells can either promote or inhibit immunity through the phosphorylation of STAT1, STAT2 and STAT3 (ref. 31) . A mainly STAT1-STAT2 response initiates the antiviral, proinflammatory response. When STAT3 expression dominates, STAT1-dependent gene expression is inhibited, which directly suppresses immunity. In addition, dominant STAT3 can indirectly alter the IFN-α signal by forming a heterodimer with STAT1, thereby inhibiting the homodimerization of STAT1 and the biological activities that are induced in response to STAT1-STAT1 homodimers 31 . By this mechanism, the IFN-α signal is shifted from a proinflammatory response to an anti-inflammatory response as a result of a change in the relative expression and activation of STAT proteins as well as their dimerization capacity. In addition, STAT1-STAT3 heterodimers have been described before; the dominance of one STAT protein over another may influence not only the activity of the STAT protein in question but also its ability to form homo-and heterodimers to mediate distinct biological outcomes. We have shown here that IL-35 induced the formation of a STAT1-STAT4 heterodimer, promoting a distinct mode of binding to the Il12a and Ebi3 promoters and activation of those genes. It is possible that STAT heterodimers may be generally linked to antiinflammatory programs.
As IL-35 seems to use receptor chains and STAT proteins similar to those used by other members of the IL-12 family, another important issue is how a T cell can 'translate' potentially similar signals into such distinct biological outcomes 16 . This enigma is certainly noted with IL-10 and IL-6. Although both cytokines signal mainly via STAT3, the outcome of their signaling and their biological activity are vastly different and have been a focus of intense research for more than a decade 30 . Thus, the use of STAT1-STAT4 heterodimers gives biochemical distinction to IL-35 signaling. However, it is still unclear why a STAT1-STAT4 heterodimer predominates after IL-35 stimulation and not after simultaneous stimulation with activators of STAT1 and STAT4, such as IFN-γ and IL-12, respectively. It is clear that gp130 and IL-12Rβ2 homodimers cannot induce both phosphorylated STAT1 and phosphorylated STAT4, which suggests that a heterodimer forms only after 'canonical' activation of gp130-IL-12Rβ2. It is possible that bringing these two receptor chains into close proximity favors the formation of STAT heterodimers that may not occur after ligation of two spatially distinct receptors. Receptors that activate STAT1 or STAT4 may be spatially segregated, preventing the formation of an anti-inflammatory STAT1-STAT4 heterodimer. Indeed, the IFN-γ receptor trafficks readily to the immunologic synapse after activation of the T cell antigen receptor, whereas IL-12R has a more diffuse localization 40, 41 . It is possible that this is needed to negate the close proximity of these receptors during T cell activation and thus prevent the inadvertent formation of STAT1-STAT4 heterodimers.
The expression pattern of IL-35R will provide insight into potential IL-35 target-cell types. Although gp130 has fairly ubiquitous expression, IL-12Rβ2 is expressed mainly by activated T cells and natural killer cells 21 . Among T cells, T H 1 cells have the highest expression of IL-12Rβ2, and its expression correlates with responsiveness to IL-12 (ref. 42 ) and IL-35. Expression of IL-12Rβ2 has also been shown on other cell types, such as dendritic cells 43 , which may affect the spectrum of IL-35 bioactivity in the immune system. IL-12Rβ2 is undetectable on most resting T cells, but it can be rapidly upregulated by exposure to IL-2, IL-12, IL-27, IFN-γ and tumor-necrosis factor and costimulation through CD28. Indeed, we have shown here that pretreatment with IL-2 or IL-27 resulted in greater sensitivity of T cells to IL-35-mediated suppression. Thus, IL-35 might have biological effects on a variety of cellular targets and under a variety of disease conditions. IL-27 is of particular interest, given its ability to npg A r t i c l e s provide inhibitory activity. Although it is thought that this is mediated in part via its induction of 45) , it is also possible that IL-27-mediated induction of IL-12Rβ2 may sensitize cells to IL-35-mediated suppression and thus may contribute to the perceived inhibitory activity of IL-27. The ability of IL-35 to mediate suppression via IL-12Rβ2-gp130 heterodimers and via IL-12Rβ2-IL-12Rβ2 and gp130-gp130 homodimers could have profound implications for its range and breadth of regulatory control. This is especially relevant for gp130, which has a broad expression pattern 21 . Indeed, use of gp130-gp130 homodimers may provide a mechanism by which IL-35 suppresses naive T cells that do not express IL-12Rβ2.
Given the potent immunosuppressive capacity of IL-35, blocking its function may be therapeutically beneficial in many disease settings. Inhibiting IL-35 activity with a neutralizing mAb to IL-35 has substantial in vivo efficacy 8 . The unique IL-35R composition of IL-12Rβ2 and gp130 presents some notable considerations and therapeutic opportunities. Animals that lack gp130 are not viable, probably because of the large number of cytokines that use gp130. For this reason it is difficult to infer that a lack of IL-35 signaling causes this phenotype. In contrast, mice lacking IL-12Rβ2 have a mildly deleterious phenotype, with reports suggesting that they are more susceptible to autoimmunity and B cell malignancies 46 . Notably, several autoimmune and inflammatory diseases have been linked to IL-12Rβ2, including atopic dermatitis, primary biliary cirrhosis, type 1 diabetes and Behçet's disease [47] [48] [49] . Together these observations suggest that the clinical consequences of dysfunction of gp130 and IL-12Rβ2 may affect immune regulation via the IL-35-IL-35R signaling axis, which suggests that further studies are needed to assess the importance of the IL-35 signaling pathway in human disease.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
